PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners

Rhea-AI Summary

PaxMedica, Inc. (Nasdaq: PXMD) has secured a funding agreement providing net proceeds of $3.2 million through a $3.68 million convertible note from Lind Global Partners II, LP. The note features an 0% interest rate and a conversion price of $3.50 per share, with repayments due in 12 monthly installments starting 180 days after funding. The CEO, Howard Weisman, expressed optimism that this capital will aid in developing PAX-101 for autism spectrum disorder (ASD). Additionally, Lind will receive a four-year warrant for 800,000 shares at $3.25 each. More details will be in a forthcoming SEC filing.

Positive

• Secured $3.2 million funding via a convertible note.
• Funding will support PAX-101 development for autism spectrum disorder.

Negative

• Repayment of the convertible note begins in 180 days, which may strain cash flow.

Additional Capital Will Help Fund Development of PAX-101

TARRYTOWN, NY, Feb. 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that the Company has signed a funding agreement for net proceeds of $3.2 million with Lind Global Partners II, LP, an investment fund managed by The Lind Partners, a New York based institutional fund manager (together “Lind”).

Howard Weisman, Chief Executive Officer of PaxMedica, commented, “We believe that this funding will give us the flexibility to progress on the work we are doing for the development of the autism spectrum disorder (ASD) indication for PAX-101. We appreciate the Lind Group’s support for our work to find treatments for disorders with intractable neurologic symptoms such as ASD.”

The new capital is in the form of a $3.68 million convertible note with an 18-month maturity, 0% annual interest rate and is convertible into Company’s common shares at a conversion price of $3.50. Commencing 180 days after funding, the Company is required to make principal payments in 12 equal monthly installments. At the discretion of the Company, repayments can be made in cash or registered common shares. Lind will also receive a four-year warrant to purchase an aggregate of 800,000 shares of common stock exercisable at $3.25 per share. The transaction is subject to the satisfaction of customary closing conditions.

Further details relating to this transaction will be contained in the Current Report on Form 8-K the Company intends to file with the Securities and Exchange Commission (the “SEC”).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any shares of common stock, nor shall there be any sale of shares of common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About The Lind Partners

The Lind Partners manages institutional funds that are leaders in providing growth capital to small- and mid-cap companies publicly traded in the US, Canada, Australia and the UK. Lind’s funds make direct investments ranging from US$1 to US$30 million, invest in syndicated equity offerings and selectively buy on market. Having completed more than 150 direct investments totaling over US$1.5 Billion in transaction value, Lind’s funds have been flexible and supportive capital partners to investee companies since 2011.

About PaxMedica

PaxMedica is a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including Autism Spectrum Disorder (“ASD”), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), a debilitating physical and cognitive disorder, believed to be viral in origin and, now with rising incidence globally due to the long term effects of SARS-CoV-2 (“COVID-19”). One of PaxMedica’s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome, a clinical diagnosis in individuals who have been previously infected with COVID-19.

For more information, please visit: www.paxmedica.com

Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements reflect our current view about future events. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and most recent quarterly reports and other filings with the U.S. Securities and Exchange Commission.

Contacts:
ir@paxmedica.com
Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
(646) 863-6341

FAQ

What amount of funding did PaxMedica secure in February 2023?

PaxMedica secured $3.2 million in funding through a convertible note.

What is the purpose of the funding received by PaxMedica?

The funding will support the development of PAX-101 for autism spectrum disorder.

What are the terms of PaxMedica’s convertible note?

The convertible note is for $3.68 million with a 0% interest rate and a conversion price of $3.50.

When does PaxMedica have to start repaying the convertible note?

PaxMedica must begin repayments 180 days after funding.

What warrants did Lind receive from PaxMedica?

Lind received warrants to purchase 800,000 shares at $3.25 per share.